Resmed End Period Cash Flow vs Sale Purchase Of Stock Analysis

RMD Stock

38.15 0.25 0.65%

Resmed financial indicator trend analysis is much more than just breaking down Resmed Inc DRC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Resmed Inc DRC is a good investment. Please check the relationship between Resmed End Period Cash Flow and its Sale Purchase Of Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

End Period Cash Flow vs Sale Purchase Of Stock

End Period Cash Flow vs Sale Purchase Of Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Resmed Inc DRC End Period Cash Flow account and Sale Purchase Of Stock. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Resmed's End Period Cash Flow and Sale Purchase Of Stock is -0.22. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Sale Purchase Of Stock in the same time period over historical financial statements of Resmed Inc DRC, assuming nothing else is changed. The correlation between historical values of Resmed's End Period Cash Flow and Sale Purchase Of Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Resmed Inc DRC are associated (or correlated) with its Sale Purchase Of Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Sale Purchase Of Stock has no effect on the direction of End Period Cash Flow i.e., Resmed's End Period Cash Flow and Sale Purchase Of Stock go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

End Period Cash Flow

Sale Purchase Of Stock

Most indicators from Resmed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Resmed Inc DRC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Resmed Inc DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to drop to about 709.4 M in 2024. Tax Provision is likely to drop to about 182 M in 2024

	2022	2023	2024 (projected)
Total Revenue	4.2B	4.7B	4.9B
Depreciation And Amortization	197.6M	216.2M	227.0M

Total Revenue Depreciation And Amortization

Resmed fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Current Deferred Revenue
Total Assets		0.58	0.75	0.89	0.97	0.92	0.74	0.98	0.95	-0.33	0.98	0.9	-0.33	0.97	-0.31	0.8	0.95	0.96	0.28	0.91	0.88	-0.17	0.9	-0.24	0.49	0.98
Short Long Term Debt Total	0.58		0.27	0.47	0.4	0.43	0.8	0.46	0.42	-0.13	0.6	0.3	-0.13	0.45	0.26	0.91	0.5	0.43	-0.22	0.84	0.44	0.14	0.76	0.22	0.47	0.49
Other Current Liab	0.75	0.27		0.71	0.79	0.74	0.42	0.78	0.71	-0.25	0.7	0.7	-0.25	0.79	-0.23	0.43	0.8	0.72	0.48	0.57	0.75	-0.08	0.55	-0.11	0.39	0.73
Total Current Liabilities	0.89	0.47	0.71		0.87	0.86	0.63	0.88	0.89	-0.28	0.89	0.82	-0.28	0.89	-0.23	0.63	0.79	0.86	0.11	0.82	0.76	0.03	0.81	-0.24	0.51	0.9
Total Stockholder Equity	0.97	0.4	0.79	0.87		0.93	0.59	0.99	0.96	-0.29	0.93	0.91	-0.29	0.98	-0.42	0.65	0.95	0.96	0.42	0.79	0.91	-0.2	0.78	-0.28	0.46	0.97
Property Plant And Equipment Net	0.92	0.43	0.74	0.86	0.93		0.47	0.92	0.89	-0.05	0.84	0.76	-0.05	0.93	-0.13	0.62	0.86	0.9	0.27	0.76	0.95	-0.13	0.7	-0.21	0.67	0.9
Net Debt	0.74	0.8	0.42	0.63	0.59	0.47		0.64	0.63	-0.65	0.83	0.67	-0.65	0.61	-0.15	0.92	0.72	0.67	-0.04	0.9	0.4	-0.21	0.94	-0.24	0.15	0.73
Retained Earnings	0.98	0.46	0.78	0.88	0.99	0.92	0.64		0.97	-0.31	0.95	0.92	-0.3	0.99	-0.38	0.7	0.94	0.94	0.34	0.83	0.9	-0.15	0.82	-0.23	0.49	0.97
Accounts Payable	0.95	0.42	0.71	0.89	0.96	0.89	0.63	0.97		-0.34	0.94	0.89	-0.33	0.96	-0.45	0.67	0.87	0.93	0.21	0.81	0.83	-0.2	0.83	-0.27	0.45	0.96
Cash	-0.33	-0.13	-0.25	-0.28	-0.29	-0.05	-0.65	-0.31	-0.34		-0.48	-0.58	1.0	-0.26	0.42	-0.35	-0.42	-0.42	-0.11	-0.36	0.1	0.58	-0.5	0.66	0.35	-0.44
Non Current Assets Total	0.98	0.6	0.7	0.89	0.93	0.84	0.83	0.95	0.94	-0.48		0.92	-0.48	0.94	-0.35	0.83	0.93	0.94	0.21	0.93	0.78	-0.24	0.95	-0.32	0.4	0.98
Non Currrent Assets Other	0.9	0.3	0.7	0.82	0.91	0.76	0.67	0.92	0.89	-0.58	0.92		-0.58	0.91	-0.5	0.61	0.88	0.89	0.38	0.74	0.68	-0.35	0.8	-0.45	0.28	0.92
Cash And Short Term Investments	-0.33	-0.13	-0.25	-0.28	-0.29	-0.05	-0.65	-0.3	-0.33	1.0	-0.48	-0.58		-0.26	0.42	-0.35	-0.42	-0.41	-0.11	-0.36	0.1	0.58	-0.5	0.66	0.34	-0.43
Net Receivables	0.97	0.45	0.79	0.89	0.98	0.93	0.61	0.99	0.96	-0.26	0.94	0.91	-0.26		-0.34	0.69	0.9	0.92	0.28	0.82	0.9	-0.14	0.81	-0.2	0.55	0.95
Common Stock Shares Outstanding	-0.31	0.26	-0.23	-0.23	-0.42	-0.13	-0.15	-0.38	-0.45	0.42	-0.35	-0.5	0.42	-0.34		0.02	-0.33	-0.4	-0.52	-0.07	-0.17	0.2	-0.2	0.26	0.41	-0.39
Non Current Liabilities Total	0.8	0.91	0.43	0.63	0.65	0.62	0.92	0.7	0.67	-0.35	0.83	0.61	-0.35	0.69	0.02		0.74	0.69	-0.09	0.96	0.59	-0.14	0.93	-0.05	0.41	0.75
Inventory	0.95	0.5	0.8	0.79	0.95	0.86	0.72	0.94	0.87	-0.42	0.93	0.88	-0.42	0.9	-0.33	0.74		0.95	0.47	0.82	0.84	-0.26	0.81	-0.33	0.36	0.94
Other Current Assets	0.96	0.43	0.72	0.86	0.96	0.9	0.67	0.94	0.93	-0.42	0.94	0.89	-0.41	0.92	-0.4	0.69	0.95		0.35	0.81	0.82	-0.33	0.82	-0.44	0.36	0.98
Other Stockholder Equity	0.28	-0.22	0.48	0.11	0.42	0.27	-0.04	0.34	0.21	-0.11	0.21	0.38	-0.11	0.28	-0.52	-0.09	0.47	0.35		-0.02	0.39	-0.11	-0.02	-0.17	-0.17	0.28
Total Liab	0.91	0.84	0.57	0.82	0.79	0.76	0.9	0.83	0.81	-0.36	0.93	0.74	-0.36	0.82	-0.07	0.96	0.82	0.81	-0.02		0.71	-0.09	0.98	-0.13	0.49	0.87
Total Current Assets	0.88	0.44	0.75	0.76	0.91	0.95	0.4	0.9	0.83	0.1	0.78	0.68	0.1	0.9	-0.17	0.59	0.84	0.82	0.39	0.71		0.04	0.63	0.0	0.65	0.82
Short Term Debt	-0.17	0.14	-0.08	0.03	-0.2	-0.13	-0.21	-0.15	-0.2	0.58	-0.24	-0.35	0.58	-0.14	0.2	-0.14	-0.26	-0.33	-0.11	-0.09	0.04		-0.18	0.71	0.16	-0.27
Intangible Assets	0.9	0.76	0.55	0.81	0.78	0.7	0.94	0.82	0.83	-0.5	0.95	0.8	-0.5	0.81	-0.2	0.93	0.81	0.82	-0.02	0.98	0.63	-0.18		-0.24	0.38	0.89
Short Term Investments	-0.24	0.22	-0.11	-0.24	-0.28	-0.21	-0.24	-0.23	-0.27	0.66	-0.32	-0.45	0.66	-0.2	0.26	-0.05	-0.33	-0.44	-0.17	-0.13	0.0	0.71	-0.24		0.15	-0.4
Common Stock	0.49	0.47	0.39	0.51	0.46	0.67	0.15	0.49	0.45	0.35	0.4	0.28	0.34	0.55	0.41	0.41	0.36	0.36	-0.17	0.49	0.65	0.16	0.38	0.15		0.41
Current Deferred Revenue	0.98	0.49	0.73	0.9	0.97	0.9	0.73	0.97	0.96	-0.44	0.98	0.92	-0.43	0.95	-0.39	0.75	0.94	0.98	0.28	0.87	0.82	-0.27	0.89	-0.4	0.41

Click cells to compare fundamentals

Resmed Account Relationship Matchups

Resmed fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.6B	4.7B	5.1B	6.8B	6.9B	7.2B
Short Long Term Debt Total	1.3B	793.7M	917.6M	1.6B	873.9M	442.7M
Other Current Liab	(54.2M)	304.1M	389.6M	365.7M	350.7M	368.2M
Total Current Liabilities	602.8M	911.8M	689.3M	758.5M	910.7M	956.2M
Total Stockholder Equity	2.5B	2.9B	3.4B	4.1B	4.9B	5.1B
Property Plant And Equipment Net	535.7M	592.1M	630.5M	665.8M	699.1M	734.1M
Net Debt	836.1M	498.4M	643.8M	1.4B	635.6M	667.4M
Retained Earnings	2.8B	3.1B	3.6B	4.3B	5.0B	5.2B
Accounts Payable	135.8M	138.0M	159.2M	150.8M	237.7M	249.6M
Cash	463.2M	295.3M	273.7M	227.9M	238.4M	333.5M
Non Current Assets Total	3.1B	3.2B	3.2B	4.4B	4.5B	4.7B
Non Currrent Assets Other	189.7M	240.8M	251.5M	395.4M	487.6M	511.9M
Cash And Short Term Investments	463.2M	295.3M	273.7M	227.9M	238.4M	338.0M
Common Stock Shares Outstanding	1.5B	1.5B	1.5B	1.5B	147.6M	140.2M
Liabilities And Stockholders Equity	4.6B	4.7B	5.1B	6.8B	6.9B	7.2B
Non Current Liabilities Total	1.5B	930.7M	1.0B	1.9B	1.1B	1.2B
Inventory	416.9M	457.0M	743.9M	998.0M	822.3M	863.4M
Other Current Assets	168.7M	296.5M	337.9M	437.0M	459.8M	482.8M
Other Stockholder Equity	(389.7M)	(415.9M)	59.2M	148.8M	123.3M	129.5M
Total Liab	2.1B	1.8B	1.7B	2.6B	2.0B	2.1B
Total Current Assets	1.5B	1.6B	1.9B	2.4B	2.4B	2.5B
Short Term Debt	33.3M	35.6M	31.8M	31.8M	35.2M	66.5M
Intangible Assets	448.2M	392.6M	345.9M	552.3M	485.9M	510.2M
Accumulated Other Comprehensive Income	(284.0M)	(193.5M)	(312.7M)	(272.5M)	(251.5M)	(239.0M)
Common Stock	580K	583K	586K	588K	676.2K	443.7K
Current Deferred Revenue	98.6M	109.6M	108.7M	138.1M	152.6M	160.2M
Good Will	1.9B	1.9B	1.9B	2.8B	2.8B	3.0B
Other Liab	221.6M	172.6M	160.0M	315.2M	362.5M	380.6M
Net Tangible Assets	158.5M	565.2M	1.1B	807.3M	726.5M	539.8M
Other Assets	145.6M	200.7M	202.3M	261.3M	300.5M	161.7M
Long Term Debt	1.2B	643.4M	765.3M	1.4B	697.3M	878.4M
Short Long Term Debt	12.0M	12M	9.9M	9.9M	9.9M	9.4M
Property Plant Equipment	535.7M	592.1M	630.5M	665.8M	765.7M	527.8M
Long Term Debt Total	1.3B	1.2B	643.4M	765.3M	688.8M	691.8M
Capital Surpluse	1.5B	1.6B	1.6B	1.7B	1.9B	1.7B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Resmed Stock Analysis

When running Resmed's price analysis, check to measure Resmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Resmed is operating at the current time. Most of Resmed's value examination focuses on studying past and present price action to predict the probability of Resmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Resmed's price. Additionally, you may evaluate how the addition of Resmed to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC